Related Experiment Videos
Metallothionein expression in hepatocellular carcinoma
Geng-Wen Huang1, Lian-Yue Yang
1Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China. hgw21@163.net
World Journal of Gastroenterology
|August 14, 2002
Summary
Metallothioneins (MTs) expression is decreased in human hepatocellular carcinoma (HCC), suggesting a role in cancer development. This finding may guide targeted chemotherapy for HCC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Metallothioneins (MTs) are proteins involved in cellular defense mechanisms.
- Recent research suggests a potential link between MTs and tumor development.
- Understanding MTs expression in hepatocellular carcinoma (HCC) is crucial for cancer research.
Purpose of the Study:
- To investigate the expression levels of metallothioneins (MTs) in human hepatocellular carcinoma (HCC).
- To explore the relationship between MTs expression and HCC development and progression.
Main Methods:
- Immunohistochemical staining using monoclonal mouse anti-MTs serum (E9) was performed on HCC tissues, adjacent non-cancerous liver tissues, and normal liver tissues.
- 35 cases of primary HCC and 5 cases of normal liver were analyzed.
- Statistical analysis was used to compare MTs expression between different groups.
Main Results:
- MTs expression was significantly lower in HCC tissues compared to normal liver and para-neoplastic tissues (P<0.01).
- MTs were expressed in 82.9% of HCC cases, with varying intensity (negative, weak, strong).
- No significant correlation was found between MTs expression in HCC and tumor size, clinical stage, or serum alpha-fetoprotein levels.
Conclusions:
- Decreased MTs expression in HCC may contribute to carcinogenesis.
- MTs are heterogeneously expressed in HCC, indicating potential for targeted therapies.
- MTs concentration in HCC could inform the selection of anticancer agents to improve chemotherapy outcomes.